Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2021 | The St. Gallen Consensus Session: loco-regional treatment

Beat Thürlimann and Michael Knauer • 22 Mar 2021
BCC 2021
Breast Cancer

Beat Thürlimann, MD, Cantonal Hospital St. Gallen, St. Gallen, Switzerland, and Michael Knauer, MD, PhD, Breast Center Eastern Switzerland, St. Gallen, Switzerland, outline the key topics discussed at the St. Gallen International Breast Cancer Consensus Session 2021. The renowned biennial consensus determines the optimal treatment of women with early breast cancer for the following two years. Prof. Thürlimann and Dr Knauer discuss the major loco-regional treatment topics from the session, including axillary dissection, omission of surgery after neoadjuvant chemotherapy, major changes in radiotherapy, and reoperation. This interview took place during the 17th St. Gallen International Breast Cancer Conference.

Disclosures

B. Thürlimann reports the following disclosures:
Receipt of honoraria or consultation fees: Amgen, AstraZeneca, Eli Lilly, MSD, Novartis, Pfizer, Roche, Daiichi-Sankyo
Stock shareholder: Novartis, Roche

More from Beat Thürlimann

Prognostic biomarkers in breast cancer – the latest developments
6:08
Prognostic biomarkers in breast cancer – the latest developments
Beat Thürlimann et al. • 22 Mar 2021
Systemic therapy at the St Gallen Consensus: multi-gene testing, Ki67, and oligometastatic disease
16:13
Systemic therapy at the St Gallen Consensus: multi-gene testing, Ki67, and oligometastatic disease
Beat Thürlimann et al. • 22 Mar 2021

More from Michael Knauer

Prognostic biomarkers in breast cancer – the latest developments
6:08
Prognostic biomarkers in breast cancer – the latest developments
Beat Thürlimann et al. • 22 Mar 2021
Systemic therapy at the St Gallen Consensus: multi-gene testing, Ki67, and oligometastatic disease
16:13
Systemic therapy at the St Gallen Consensus: multi-gene testing, Ki67, and oligometastatic disease
Beat Thürlimann et al. • 22 Mar 2021
COVID-19 experience in Switzerland
2:12
COVID-19 experience in Switzerland
Michael Knauer • 7 May 2020
The role of surgery in metastatic breast cancer
3:50
The role of surgery in metastatic breast cancer
Michael Knauer • 29 Apr 2020

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals